Recent studies have centered on the intersection of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|GCGR stimulant therapies and dopamine neurotransmission. While GCGR activators are commonly employed for managing type 2 diabetes, their potential consequences on reinforcement circuits, specifically governed by dopaminergic netw